SCHEMBL2300372

SCHEMBL2300372

CCOc1c(C(=O)O)c(C(=O)O)c(OCC)c2ccccc12.[NaH]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 4/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 1/20 0.46
GLA P06280 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 7/20 0.43
HPGD P15428 7/20 0.43
KDM4E B2RXH2 6/20 0.43
HSD17B10 Q99714 4/20 0.43
MAPK1 P28482 2/20 0.43
RECQL P46063 1/20 0.43
LMNA P02545 3/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
CYP2C19 P33261 1/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299912 0.98 PTGER4 (0.47) PTGER4CYP1A2CYP2D6GLAL3MBTL1
SCHEMBL2300382 0.96 PTGER4 (0.46) PTGER4CYP1A2CYP2D6GLAL3MBTL1
SCHEMBL11967633 0.90 CASP3 (0.44) PTGER4CYP1A2CYP2D6GLAL3MBTL1
SCHEMBL9606731 0.90 KDM4E (0.43) PTGER4CYP1A2CYP2D6GLAL3MBTL1
SCHEMBL3569001 0.90 PTGER4 (0.42) PTGER4CYP1A2CYP2D6GLAL3MBTL1
SCHEMBL3564213 0.89 KDM4E (0.50) CYP1A2CYP2D6L3MBTL1ALDH1A1HPGD
SCHEMBL1590143 0.89 ALDH1A1 (0.49) PTGER4CYP1A2CYP2D6ALDH1A1HPGD
SCHEMBL3564311 0.87 PTGER4 (0.40) PTGER4CYP1A2CYP2D6GLAL3MBTL1
SCHEMBL2297210 0.84 KMT2A (0.46) PTGER4CYP1A2GLAL3MBTL1ALDH1A1
SCHEMBL3559690 0.82 TSHR (0.46) PTGER4CYP1A2L3MBTL1CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252833-B2 Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists GLAXO GROUP LIMITED (GB) 2012-08-28 US disclosed
EP-2457897-A1 BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS Glaxo Group Limited (GB) 2012-05-30 EP disclosed
US-20110201663-A1 BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201663-A1 BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS PTGER4, PTGER1, PTGER2 PTGER4 1/4885CYP1A2 284/4885CYP2D6 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.